<DOC>
	<DOCNO>NCT01222637</DOCNO>
	<brief_summary>This prospective , open label , multicenter study evaluate safety , tolerability pharmacokinetics CetuGEX™ intravenous administration patient EGFR positive , locally advanced and/or metastatic solid cancer . The effect CetuGEX™ development anti-drug antibody tumour response also evaluate .</brief_summary>
	<brief_title>CetuGEX™ : Dose Escalation Study</brief_title>
	<detailed_description />
	<criteria>1 . Male female age ≥ 18 yr 2 . Histologically confirm EGFR positive locally advanced and/or metastatic solid organ tumour 3 . Measurable nonmeasurable tumour 4 . Failure standard therapy nonavailability standard therapy ( Patients must receive least 1 line chemotherapy standard therapy option study entry ) 5 . All antitumour therapy must complete 4 week start study treatment ; treatment Cetuximab must complete least 6 week prior study start 6 . ECOG Performance Status ≤1 estimate life expectancy ≥ 3 month 7 . Adequate organ function : Bone marrow function : hemoglobin ≥ 100 g/L ; white blood cell count ( WBC ) ≥ 3.0 x 10^9/L ; absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L ; platelet count ≥ 100 x 10^9/L Hepatic : aspartate aminotransferase ( ASAT ) alanine aminotransferase ( ALAT ) ≤ 2.5 time upper limit normal ( ULN ) ( ≤ 5 x ULN hepatic metastasis present ) ; bilirubin ≤ 1.5 x ULN ; alkaline phosphatase ≤ 5.0 x upper limit normal ( ULN ) Renal : creatinine &lt; 1.5 x ULN 8 . Patients gender procreative potential must use effective contraception enrol study least 4 week last study drug infusion 9 . Written informed consent must obtain prior conduct studyspecific procedure For Expansion Phase : 10 . No prior treatment Cetuximab allow 1 . Chemotherapy , radiation , anticancer therapy include investigational agent study enrolment within 4 week prior study enrolment 2 . Concurrent antitumour therapy concurrent immunotherapy 3 . Concurrent systemic steroid except topical ( inhaled , topical , nasal ) replacement therapy last 28 day . 4 . Major surgery within 4 week prior enter study and/or incomplete recovery surgery plan major surgery 5 . Primary secondary immune deficiency 6 . Clinically active infection &gt; CTCAE grade 2 7 . Prior allergic reaction monoclonal antibody ( e.g . Trastuzumab , Cetuximab Bevazicumab ) . 8 . Active hepatitis B assess serology , hepatitis C histology ; human immunodeficiency virus ( HIV ) seropositivity 9 . Any concurrent malignancy basal cell carcinoma carcinoma situ cervix . Patients previous malignancy without evidence disease ≥ 3 year allow enter study . 10 . Uncontrolled medical condition consider high risk treatment investigational drug include unstable diabetes mellitus , venacavasyndrome , chronic symptomatic respiratory disease . 11 . Clinical sign brain metastasis leptomeningeal involvement 12 . Symptomatic congestive heart failure ( New York Heart Association [ NYHA ] 3 4 ) ; unstable angina pectoris within 6 month prior enrollment ; significant cardiac arrhythmia , history stroke transient ischemic attack within 1 year . 13 . Active drug abuse chronic alcoholism 14 . Pregnancy Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>advanced solid cancer</keyword>
	<keyword>metastatic solid cancer</keyword>
</DOC>